A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the absorption (the way the drug enters the
body), metabolism (the way the drug is broken down in the body), and excretion (the way drug
leaves the body) of canagliflozin (JNJ-28431754) in healthy male volunteers after a single
dose of radiolabeled 14C-canagliflozin (14C-JNJ-28431754). The safety and tolerability of
canagliflozin will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.